The board of Cinevista Ltd has approved the sub-division of Rs 10 to Rs 2 per share.
Further, the board has decided to increase the authorized capital from Rs 12 crore to Rs 20 crore.
Ranbaxy Laboratories has received approval from the U.S. Food and Drug Administration to manufacture and market hydrocodone bitartrate and acetaminophen tablets USP, 75 mg/750 mg, 10 mg/500 mg, 5 mg/500 mg, and 10 mg/325 mg strengths. The office of generic drugs, U.S. FDA, has determined the Ranbaxy formulations to be bioequivalent and have the same therapeutic effect as that of the reference listed drugs as follows: 10 mg/325 mg norco tablets of watson pharmaceuticals 5 mg/500 mg vicodin tablets, and 7.5 mg/750 mg vicodin ES tablets both of abbott laboratories, and 10 mg/500 mg lortab tablets of UCB Inc.